Cypherpunk Technologies Inc (CYPH)

Cypherpunk Technologies Inc. is a NASDAQ-listed common stock company based in Cambridge, Massachusetts. The business combines a privacy technology focus with a digital asset strategy centered on Zcash in the United States. Its activities include identifying, developing, investing in, acquiring, and building privacy-enhancing technologies, as well as accumulating digital assets such as Zcash. In parallel, the company continues to develop a clinical-stage biotechnology pipeline. That pipeline includes DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1 and has completed a Phase 2 study in colorectal cancer, and FL-501, a monoclonal antibody targeting GDF-15 that is in preclinical development for cancer cachexia, hyperemesis gravidarum, pregnancy-related nausea and vomiting, and other conditions associated with aging and frailty. The company was incorporated in 2011 and adopted its current name in November 2025; it was previously known as Leap Therapeutics, Inc.

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.